Le Lézard
Classified in: Covid-19 virus
Subject: Business Update

SelectQuote, Inc. Reports Preliminary Second Quarter 2023 Results and Raises Full Year 2023 Guidance


SelectQuote, Inc. (NYSE: SLQT), a pioneer in providing consumers with unbiased price comparisons from some of the most trusted insurance carriers, today announced preliminary financial results for the second quarter of fiscal year 2023.

Second Quarter 2023 Preliminary Results

Guidance for the Full Year 2023

Chief Executive Officer Tim Danker commented, "SelectQuote's impressive preliminary second quarter results reflect strong performance during the 2022 Medicare Advantage annual enrollment period and continued execution against the strategic redesign we initiated last year. The Company's strategy to employ a higher mix of tenured core Senior agents and onboard those agents earlier in the season has proven fruitful, with year-over-year increases in close rates. Additionally, we have improved marketing costs per approved policy through more focused lead targeting and selection. We are incredibly proud of our progress so far this year within our Medicare distribution business and with the unit economics delivered during the second quarter."

Mr. Danker continued, "We also continue to invest in the growth of our Healthcare Services segment and will share updates on our fiscal second quarter earnings call in February. We reiterate that SelectQuote began fiscal year 2023 with sufficient liquidity to support our intended operating plan. Year-to-date we are ahead of our original cash forecast, and these preliminary second quarter results strengthen our conviction that we will achieve cash EBITDA breakeven during fiscal year 2023."

Forward Looking Statements

This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "could," "predict," "potential," "believe," "will likely result," "expect," "continue," "will," "anticipate," "seek," "estimate," "intend," "plan," "projection," "would" and "outlook," or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: the ultimate duration and impact of the ongoing COVID-19 pandemic and any other public health events, our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, including exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers' approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; and failure to market and sell Medicare plans effectively or in compliance with laws. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled "Risk Factors" in the most recent Annual Report on Form 10-K (the "Annual Report") and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA and cash EBITDA, which are non-GAAP financial measures. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly titled measures presented by other companies. We define Adjusted EBITDA as income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and certain add-backs for transaction costs and non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. We define cash EBITDA as Adjusted EBITDA excluding the impacts from the estimates of future renewal commission revenue. The most directly comparable GAAP measure for both Adjusted EBITDA and cash EBITDA is net income (loss). We monitor and have presented in this release Adjusted EBITDA and cash EBITDA because they are key measures used by our management and Board of Directors to understand and evaluate our operating performance, to establish budgets and to develop operational goals for managing our business. In particular, we believe that excluding the impacts of certain transactions in calculating Adjusted EBITDA and cash EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.

We believe that these non-GAAP financial measures help identify underlying trends in our business that could otherwise be masked by the effect of the transactions that we exclude in the calculations of these non-GAAP financial measures. Accordingly, we believe that these financial measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects.

The following tables present reconciliations of Adjusted EBITDA to net income (loss):

Second quarter 2023 preliminary results

     

(in thousands)

   

Range

Net income

   

$

11,000

 

$

23,000

Income tax expense

   

 

2,000

 

 

7,000

Interest expense, net

   

 

19,000

 

 

19,000

Depreciation and amortization

   

 

6,000

 

 

6,000

Share-based compensation expense

   

 

3,000

 

 

3,000

Transaction costs

   

 

4,000

 

 

2,000

Adjusted EBITDA

   

$

45,000

 

$

60,000

Fiscal year 2023 guidance

     

(in thousands)

   

Range

Net loss

   

$

(98,000

)

 

$

(78,000

)

Income tax benefit

   

 

(28,000

)

 

 

(25,000

)

Interest expense, net

   

 

74,000

 

 

 

74,000

 

Depreciation and amortization

   

 

24,000

 

 

 

24,000

 

Share-based compensation expense

   

 

12,000

 

 

 

12,000

 

Transaction costs

   

 

16,000

 

 

 

18,000

 

Adjusted EBITDA

   

$

?

 

 

$

25,000

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) provides solutions that help consumers protect their most valuable assets: their families, health, and property. The company pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads.

With an ecosystem offering high touchpoints for consumers across Insurance, Medicare, Pharmacy, and Value-Based Care, the company now has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with best-in-class healthcare services that fit each member's unique healthcare needs. The platform improves health outcomes and lowers healthcare costs through proactive engagement and access to high-value healthcare solutions.

*See "Non-GAAP Financial Measures" for additional information regarding the non-GAAP financial measures referenced in this release.


These press releases may also interest you

at 11:35
Victoria Gold Corp. ("Victoria" or the "Company") provides an update on the heap leach facility ("HLF") incident that occurred at the Eagle Gold Mine on June 24, 2024 (see Company News Release dated June 24, 2024). As initially reported, there were...

at 10:16
The global Sports Composites Market, valued at $4.73 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $6.2 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031,...

at 10:15
According to SkyQuest, the global Artificial Intelligence (AI) in Retail Market is valued at USD 5.59 Billion in 2022 and is expected to grow from USD 7.42 Billion in 2023 to reach USD 71.23 Billion by 2031, at a CAGR of 32.68% during the forecast...

at 10:11
The Prime Minister, Justin Trudeau, today announced the reappointment of Dr. Mona Nemer as Canada's Chief Science Advisor for a term of three years, effective September 25, 2024. A distinguished medical researcher, Dr. Nemer has served as Canada's...

at 10:05
The "The Worldwide Market for Clinical Laboratory Services, 9th Edition" report has been added to ResearchAndMarkets.com's offering. Stay ahead with insights into demographic trends, disease trends, new developments, company performance, mergers...

at 10:01
The global Industrial Insulators Market, valued at $4.29 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $6 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.9% from 2024 to...



News published on and distributed by: